Beyond Breakthroughs: Building Sustainable and Inclusive Cancer Care

The International Journal of Cancer Care and Delivery (IJCCD) was founded with a clear and deliberate mission: to disseminate clinically meaningful, accessible, and forward-looking oncology research that informs real-world practice while addressing persistent gaps in cancer care delivery. As the official journal of Binaytara, IJCCD is uniquely positioned at the intersection of science, equity, and implementation. The five articles in this issue exemplify this mission, spanning molecular precision oncology, therapeutic innovation, survivorship and supportive care, health disparities, and evolving treatment paradigms in historically lethal malignancies.

Collectively, these contributions underscore a central theme: progress in oncology is no longer defined solely by drug approvals or survival curves, but by our ability to deliver the right therapy to the right patient at the right time, while focusing on equity, sustainability, and quality of life.

The review on adjuvant therapy for localized colon cancer¹ highlights how rapidly the management of early-stage disease is evolving. Historically, adjuvant treatment decisions relied largely on clinicopathologic features and consisted of chemotherapy or surveillance. Today, molecular stratification, particularly mismatch repair (MMR) and PIK3CA status, impacts treatment decisions. In the future, circulating tumor DNA (ctDNA) has the potential to reshape the therapeutic landscape.

The authors thoughtfully synthesize emerging data supporting chemoimmunotherapy as a new standard in stage III mismatch repair-deficient (dMMR) colon cancer, while also addressing the nuanced role of neoadjuvant immunotherapy in select high-risk settings. Importantly, the discussion around ctDNA illustrates both promise and caution: while ctDNA offers unprecedented sensitivity for detecting minimal residual disease, for now it must complement, rather than replace, clinical judgment and established risk factors. Validation of survival benefits is necessary to rule out lead-time bias. Also, prospective comparisons of various ctDNA assays are needed to identify the optimal test for a specific application. From an implementation science perspective, substantial barriers may limit the adoption of such high‑complexity testing in community settings, including but not limited to turnaround time, cost, the expertise required for interpretation, and the incorporation of findings into patient management. Targeted efforts are needed to mitigate these challenges.

Equally notable is the emphasis on adjunctive interventions, including aspirin in PIK3CA-mutated disease and structured exercise programs. These strategies remind us that meaningful survival gains may come not only from novel agents, but also from rigorously studied, low-cost, scalable interventions, particularly relevant for global oncology and resource-constrained settings.

The review addressing locally advanced and metastatic urothelial carcinoma (la/mUC)² captures one of the most dramatic paradigm shifts in solid tumor oncology in recent years. The approval of enfortumab vedotin plus pembrolizumab as first-line therapy has fundamentally altered expectations for survival in a disease long marked by poor outcomes and high treatment attrition. However, comparative effectiveness research is essential here as real-world data is needed to evaluate outcomes in patients in clinics who may not fit the trial inclusion criteria.

Beyond summarizing trial results, this article excels in addressing the real-world challenges that accompany rapid therapeutic advances: treatment sequencing after frontline antibody–drug conjugate (ADC)–based regimens, management of cumulative toxicities such as neuropathy and dermatologic effects, and the growing urgency for biomarkers to guide treatment duration and de-escalation.

The discussion of perioperative immunotherapy and ADCs further illustrates a recurring theme in modern oncology: boundaries between localized and metastatic disease are increasingly blurred. As therapies move earlier in the disease course, clinicians must anticipate downstream implications for resistance, retreatment, and survivorship, an area where real-world data and implementation science will be critical.

The review on Cancer Health Disparities³ serves as a powerful reminder that scientific progress alone is insufficient if its benefits are inequitably distributed. This article moves beyond describing disparities to examining actionable frameworks, particularly community-engaged research models, that can meaningfully improve representation, trust, and outcomes.

Lessons from COVID-19 vaccine trials are especially instructive for oncology with regard to community engagement to foster education, recruitment and retention in clinical trials. Structural racism, underrepresentation in clinical trials, and limited access to specialty care remain pervasive barriers. The authors make a compelling case for embedding equity at every stage of research and care delivery, from trial design and enrollment to workforce diversification and policy advocacy.

For IJCCD, this work reinforces the journal's commitment to publishing scholarship that addresses not only which treatments work, but also for whom, where, and under what conditions they can be delivered effectively.

The review exploring extensive-stage small cell lung cancer (ES-SCLC)⁴ reflects the growing biological and therapeutic complexity of a disease once considered monolithic. Agents such as lurbinectedin and tarlatamab have added treatment options for this deadly disease. The real-world effectiveness and quality-adjusted life years of these agents need to be evaluated for patients who may not have met clinical trial criteria. Molecular subtyping, novel investigational agents, targets based on resistance patterns, and the integration of immunotherapy and radiotherapy signal a shift towards a more personalized approach in ES-SCLC historically treated with uniform regimens.

The discussion of subtype-specific vulnerabilities and the potential role of consolidative radiotherapy in the immunotherapy era highlights how the treatment landscape will continue to evolve for ES-SCLC. While survival remains poor for most patients with ES-SCLC, these advances offer cautious optimism and underscore the need for continued investment in biomarker-driven trials.

The final review⁵ articulates a compelling framework for addressing persistent cancer health inequities through sustainable, multisector partnerships, targeting patient care, improving quality of life and mitigating financial toxicity by involving employers/insurers, task-shifting, and leveraging technology, across both high-income countries (HICs) and low- and middle-income countries (LMICs). Despite overall improvements in cancer mortality in HICs, substantial disparities persist based on socioeconomic status, race/ethnicity, rurality, and access to care. In LMICs, these challenges are magnified by fragmented health systems, workforce shortages, limited infrastructure, and rising cancer incidence, resulting in disproportionately high mortality rates despite lower overall cancer prevalence.

The authors argue that the medicalization and rising cost of cancer care, without parallel investment in patient-centered and supportive services, have exacerbated financial toxicity and undermined quality of life, particularly for disadvantaged populations. To counter these trends, the review emphasizes partnership-driven models that link patients and caregivers to comprehensive resources across the cancer continuum, including prevention, diagnosis, treatment, survivorship, and palliative care. It is important to recognize financial toxicity as a distinct "adverse event" and formally incorporate it into clinical oncology grading systems.^6,7

Drawing on examples from the American Cancer Society, the authors highlight effective partnership strategies, such as patient navigation programs, national and global Roundtables, and "hub-and-spoke" academic–community networks, that improve access to high-quality care and clinical trials. These models demonstrate how shared leadership, coordinated planning, and alignment around common goals, guided by the collective impact framework which can overcome siloed care delivery and duplication of efforts.

Importantly, the authors extend these principles globally, illustrating how adaptable partnership models can strengthen cancer care capacity in LMICs through task-shifting, workforce development, employer and insurer engagement, and the strategic use of digital health technologies. The review concludes that centering patients, caregivers, and communities within these partnerships is essential to achieving durable improvements in equity, quality of life, and outcomes worldwide.

Taken together, these five articles exemplify the core ethos of IJCCD. They remind us that the future of oncology lies not only in innovation, but in implementation, ensuring that advances are deliverable, tolerable, equitable, and informed by real-world constraints.

US reports consultancy to Astellas, AstraZeneca, Adaptimmune, Exelixis, Flatiron Health, Gilead, Imvax, Janssen, Kairos, Pfizer, Seattle Genetics, and Sanofi and research funding to institute from Janssen, Exelixis and Astellas/Seattle Genetics.

N/A

N/A

N/A

N/A

N/A

N/A

Concept and design: US

Data acquisition: US

Data analysis and interpretation: US

Drafting of the manuscript: US

Critical revision of the manuscript: US

US approved the final version of the manuscript and agree to be accountable for all aspects of the work, in accordance with the International Committee of Medical Journal Editors criteria.

1. Hsieh RW, Sahin IH. Adjuvant therapy for patients with localized colon cancer. Int J Cancer Care Deliver. 2025;5(2):1-9.

2. Ozay ZI, Swami U. Advancing treatment for locally advanced and metastatic urothelial carcinoma: adopting advancements and navigating challenges. Int J Cancer Care Deliver. 2025;5(2):1-6.

3. Huynh T, Islam J, Aboulafia D. Evolving the research landscape toward cancer health equity: a mini-review on cancer health disparities. Int J Cancer Care Deliver. 2025;5(2):1-11.

4. Reddy S, Thawani R. Recent advances in extensive stage small cell lung cancer. Int J Cancer Care Deliver. 2025;5(2):1-14.

5. Sivendran S, Kamal A, Agrawal A. Building sustainable partnerships for cancer health equity. Int J Cancer Care Deliver. 2025;5(2):1-11.

6. Tran BT, et al. Validation of the comprehensive score for financial toxicity (COST) in Vietnamese patients with cancer. PLoS One. 2024;19(6):e0306339.

7. Khera N. Reporting and grading financial toxicity. J Clin Oncol. 2014;32(29):3337-3338.